Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor

2024-9-15

Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer

2024-9-15

Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution

2024-9-12

Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

2024-9-11

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of alectinib and pembrolizumab for the adjuvant treatment of non-small cell lung cancer in Japan

2024-9-11

Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data

2024-9-9

Local extension findings on MRI compensate for the ability of pathological staging to predict oncological outcome

2024-9-9

Maediastinal germ cell tumors: analysis using hospital-based cancer registry data in Japan

2024-9-5

Out-of-pocket fertility preservation expenses: data from a Japanese nationwide multicenter survey

2024-9-4

Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan

2024-9-2

Long-term outcomes of sentinel lymph node navigation surgery for early-stage cervical cancer

2024-9-2

Current status of BAFF targeting immunotherapy in B-cell neoplasm

2024-9-2

Identification of clinical prognosis features and significant DNA methylation regulation in pineoblastoma

2024-8-30

Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study

2024-8-28

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

2024-8-27

Correction to: Real‑world practice of estrogen therapy after surgery for endometrial cancer: a descriptive study using a Japanese claims database

2024-8-27

Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers

2024-8-26

Impact of interstitial lung disease gender-age-physiology index in surgically treated lung cancer

2024-8-24

Research on biomarkers using innovative artificial intelligence systems in breast cancer

2024-8-24

Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients

2024-8-23

Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma

2024-8-23

Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study

2024-8-18

A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide

2024-8-17

Prognosis of early-onset vs. late-onset stage II/III colorectal cancer patients with adjuvant chemotherapy: a multicenter propensity score matched study

2024-8-14

Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era

2024-8-14

Correction to: Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan

2024-8-13

Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis

2024-8-7

Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective study

2024-8-7

Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan

2024-8-1

Advances in the treatment of human epidermal growth factor receptor 2-positive gastric cancer

2024-7-31

Prognostic value of pretreatment temporal muscle thickness after curative surgery for oral cavity squamous cell carcinoma

2024-7-30

Severe weight loss during PD-1 treatment is a risk sign of poor prognosis for advanced GC patients

2024-7-30

Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab

2024-7-24

Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer

2024-7-23

Comorbid thrombosis as an adverse prognostic factor in patients with ovarian clear cell carcinoma regardless of staging

2024-7-22

A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity

2024-7-19

Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations

2024-7-17

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer

2024-7-15

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval selpercatinib for solid tumor with RET fusion, gumarontinib for non-small cell lung cancer with MET gene exon 14 skipping mutation, momelotinib for myelofibrosis, bexarotene for adult T-cell leukemia/lymphoma, valemetostat for peripheral T-cell lymphoma, and pirtobrutinib for mantle cell lymphoma in Japan

2024-7-15

Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study

2024-7-13

The diagnostic and prognostic value of tartrate-resistant acid phosphatase isoform 5b for giant cell tumor of bone

2024-7-12

Long-term consequences of positive surgical margin after partial nephrectomy for renal cell carcinoma: multi‐institutional analysis

2024-7-9

Endoscopic and exoscopic surgery for brain tumors

2024-7-8

Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement

2024-7-8

Measurement of the distance between tumor micro-foci and gross tumor in rectal cancer pathological specimens: implication on margin distance of clinical target volume treated with high-dose radiotherapy for rectal cancer

2024-7-8

Endoscopic ultrasound-guided hepaticogastrostomy vs. antegrade metal stent placement keeping an access route in patients with malignant biliary obstruction

2024-7-7

Pancreatic cancer and sarcopenia: a narrative review of the current status

2024-7-2

Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan

2024-7-2

Immunotherapy for endometrial cancer

2024-6-24

Association between hospital palliative care team intervention volume and patient outcomes

2024-6-24